Comparative Effect of Oxymetazoline 0.1% (Upneeq) and Brimonidine 0.025% (Lumify) on Upper Eyelid Position in Acquired Ptosis: A Randomized, Double-Masked, Crossover Study

This study aims to compare the short-term effect of oxymetazoline 0.1% (Upneeq) versus brimonidine 0.025% (Lumify) on upper-eyelid position in adults with acquired ptosis. Participants will undergo standardized eyelid photography, receive a single dose of either Upneeq or Lumify in randomized order, and have repeat photographs approximately 60 minutes later. They will return for a second visit to receive the alternate medication using the same procedures. Eyelid height measurements will be obtained from coded images by masked graders. Data will be analyzed using paired statistical methods appropriate for a crossover design. Both medications are FDA-approved topical ophthalmic drops, and the study involves minimal risk with anticipated transient ocular irritation as the most common adverse event.

Start Date01 Dec 2026

Sponsor / Collaborator

Duke University

NCT04007276

/ Not yet recruitingPhase 4IIT

The Effect of Lumify™ (Brimonidine Tartrate Ophthalmic Solution 0.025%) on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients Using Brimonidine 0.2%, 0.15%, or 0.1%

Glaucoma represents a group of conditions that cause damage to the optic nerve and can lead to irreversible vision loss. Current treatments are aimed at lowering intraocular pressure while minimizing medication side effects. Lumify™ (Brimonidine Tartrate Ophthalmic Solution 0.025%) is an FDA-approved medication for alleviating eye redness, a common side effect of glaucoma medications. The purpose of this study is to evaluate the effect of Lumify™ on eye redness, intraocular pressure, and eyelid position in patients with glaucoma who are already using the Brimonidine 0.1%, 0.15% or 0.2% eye drops.

Start Date10 Nov 2026

Sponsor / Collaborator-

JPRN-jRCTs031260199

/ RecruitingPhase 4

Study to Investigate the Prolonged Effects of Faricimab Combined with Eye Drops for the Treatment of Neovascular Age-Related Macular Degeneration

Start Date08 Jun 2026

Sponsor / Collaborator-

100 Clinical Results associated with Brimonidine Tartrate

100 Translational Medicine associated with Brimonidine Tartrate

100 Patents (Medical) associated with Brimonidine Tartrate

2,467

Literatures (Medical) associated with Brimonidine Tartrate

01 Jul 2026·SUPPORTIVE CARE IN CANCER

TAR-0520, a new candidate in oncodermatology: Results of a phase 1 program in healthy volunteers

Article

Author: Czernielewski, Janusz ; Lamquin, Alexandra ; Andres, Philippe ; Winckle, Gareth

PURPOSE:

TAR-0520 gel is a new topical formulation of brimonidine tartrate designed to prevent chemotherapy-induced skin toxicities. We report here the main outcomes of the phase 1 program which included two double-blind, randomized trials in healthy volunteers (TAR006 and TAR012) and were performed to evaluate the safety, local tolerability, pharmacokinetics, and pharmacodynamics (PD) of TAR-0520 gel.

METHOD:

In TAR006, participants received four concentrations of TAR-0520 gel (0.5%, 0.75%, 1% and 1.5% of Brimonidine tartrate), placebo, or active comparator (Mirvaso® Galderma International, France) applied daily to the chest for 21 days, while TAR012 evaluated TAR-0520 gel 1% and 1.5% on the chest and face over the same duration. Local tolerance was assessed daily in both studies using mean cumulative irritation index and maximum irritation score as key endpoints. Skin blanching was assessed via chromameter-measured reductions in skin redness as a marker of vasoconstriction and product potency. In TAR006, systemic exposure to brimonidine tartrate was assessed from blood samples collected in a separate cohort treated with TAR-0520 gel 1%.

RESULTS:

Overall, 28 participants were randomized in TAR006 and 26 were randomized in TAR012. Both studies showed excellent local tolerance with 50 healthy volunteers reporting no evidence of irritation with any treatment and four patients reporting barely perceptible minimal erythema. No adverse events related to TAR-0520 gel were reported. Minimal systemic absorption was observed that was not considered to be clinically relevant. PD studies indicated dose-dependent vasoconstriction with once-daily use lasting over 24 h.

CONCLUSION:

Under the conditions of these studies, TAR-0520 gel presents a very favorable safety profile with little to no local irritation and insignificant systemic exposure. Allowing a superficial skin vasoconstriction over a period of 24 h, it offers a safe, patient-friendly, and adaptable topical solution. The 1.5% concentration was selected for further development and phase II trials for managing chemotherapy-related skin toxicities are in progress.

REGISTRATION DETAILS:

- TARIAN 006, 2023-504178-39-00 approved 24/08/203. - TARIAN 012, 2324CMCL096 approved 28/05/2024.

01 Jul 2026·Ophthalmology and Therapy

Treatment Persistence with Combination Eye Drops for Glaucoma: A Longitudinal Analysis Using Japanese Medical Claims Data

Article

Author: Toda, Rikiya ; Matsukawa, Miyuki ; Michikami, Daisaku ; Okamoto, Kana ; Kashiwagi, Kenji

INTRODUCTION:

Glaucoma is a chronic progressive disease and the leading cause of blindness, particularly among older individuals. Treatment persistence with intraocular pressure (IOP)-lowering therapy is essential to avoid visual impairment, although data on persistence with combination eye-drop therapy are lacking. The objective of this study was to evaluate treatment persistence with combination eye-drop therapy in Japanese patients with glaucoma or ocular hypertension.

METHODS:

This longitudinal cohort study analysed anonymised insurance claims data from the DeSC database. Adults (≥ 18 years) with glaucoma or ocular hypertension who initiated IOP-lowering therapy within the same month as their diagnosis between June 2020 and May 2023 were included. The primary outcomes were: (1) treatment persistence among patients who initiated carteolol/latanoprost-based combination therapy (research question [RQ] 1); (2) persistence according to the number of bottles and active IOP-lowering ingredients (RQ2); (3) persistence according to the number of bottles of eye drops (RQ3); and (4) persistence according to concomitant use of different IOP-lowering drugs (RQ6).

RESULTS:

Among patients who initiated carteolol/latanoprost (RQ1 cohort; n = 28,560), the 360-day persistence rates were highest with concomitant brimonidine/brinzolamide (23.0%) and lowest with ripasudil (16.5%). The median duration of persistence was longer with concomitant brimonidine or brimonidine/brinzolamide versus concomitant brinzolamide, ripasudil or dorzolamide (148 vs 130, 120 and 117 days, respectively). Persistence also increased with increasing number of active IOP-lowering ingredients (RQ2 cohort; two-bottles, n = 160,481; three-bottles, n = 48,994) but declined with increasing number of bottles of eye drops (RQ3 cohort; n = 188,676). Combination therapy with a β-blocker plus a prostaglandin F2α receptor agonist showed a trend towards having the longest persistence duration, while β-blocker plus carbonic anhydrase inhibitor regimens showed a trend towards the shortest duration (RQ6).

CONCLUSION:

These findings suggest that treatment persistence with combination eye-drop therapy in Japanese patients with glaucoma or ocular hypertension may differ depending on the IOP-lowering regimen.

01 Jun 2026·BIOLOGICAL PSYCHIATRY

Oral Clonidine and Brimonidine Eye Drops Attenuated Sertraline Discontinuation Symptoms

Letter

Author: Blier, Pierre ; El Mansari, Mostafa ; Almatrafi, Asma

News (Medical) associated with Brimonidine Tartrate

20 Aug 2026

·www.prnewswire.com

Lupin and Tenpoint Therapeutics Announce Strategic Partnership to Commercialize YUVEZZI™ in the European Union, the United Kingdom, Switzerland, Norway, and Iceland

Demonstrates a shared commitment to extend global access for the only once-daily dual-agent presbyopia-correcting eye drop in the rapidly growing presbyopia vision management segment MUMBAI, India and NAPLES, Fla. and WARREN, New Jersey and AMSTERDAM and LONDON, Aug. 20, 2026 /PRNewswire/ -- Global pharma major Lupin Limited ("Lupin") (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that VISUfarma B.V. ("VISUfarma"), a wholly owned subsidiary of Lupin, has entered into an exclusive licensing agreement with Visus Therapeutics Inc., U.S.A., a wholly owned subsidiary of Tenpoint Therapeutics Holding Limited ("Tenpoint"). This partnership provides VISUfarma the exclusive rights to undertake regulatory activities, commercialization, marketing, promotion, distribution and sale of YUVEZZI™ (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%, a proprietary ophthalmic product indicated for the treatment of presbyopia in adults, in the European Union, the United Kingdom, Switzerland, Norway and Iceland (Licensed Territories). Continue Reading Tenpoint Therapeutics Logo Under the agreement, VISUfarma will make a strategic investment in Visus. Tenpoint and Visus, individually or collectively, will also be eligible to receive regulatory and commercial milestone payments, as well as tiered royalties based on net sales. Vinita Gupta, Chief Executive Officer, Lupin, said, "We are delighted to partner with Tenpoint Therapeutics to bring a novel ophthalmic therapy that advances our Specialty Care strategy. Building on the strategic acquisition of VISUfarma, this partnership further strengthens our vision care franchise and expands our presence across key European markets. The addition of YUVEZZI™ underscores our commitment to broadening access to differentiated therapies, improving patient outcomes, and reinforcing our leadership in eye care across the Licensed Territories." "This exciting partnership marks an important step for Tenpoint as we continue our work to make YUVEZZI™ available for the millions of patients with presbyopia and eye care professionals around the world," said Henric Bjarke, Chief Executive Officer, Tenpoint. "Lupin's strong commercial operations span major European markets, and its specialty ophthalmology company VISUfarma's longstanding presence in eyecare makes them an excellent partner. We look forward to working together as we bring YUVEZZI™ to Europe." As the first and only approved once-daily, dual-agent eye drop for presbyopia, YUVEZZI™ represents a significant advancement in eye care. The addition of YUVEZZI™ enhances Lupin's ophthalmology portfolio and supports the company's strategy for expanding its specialty care business through innovative therapies that address significant unmet patient needs. Tenpoint is advancing commercialization of YUVEZZI™ in the United States following its recent U.S. FDA approval. This further expands the reach of YUVEZZI™ through strategic regional partnerships worldwide, and Tenpoint has already submitted an MMA in the UK, via the MHRA's International Recognition Procedure. It will continue to execute its plans for regulatory applications for YUVEZZI™ in other key regions worldwide. About Lupin Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with a strong presence across India, the U.S., Other Developed Markets, and Emerging Markets, with products distributed in over 100 markets. Lupin has a diversified portfolio spanning generics, complex generics, specialty medicines, and biosimilars, and continues to strengthen its market position through a differentiated portfolio. The company maintains strong leadership in the U.S. and India across core therapeutic areas, including cardiovascular, respiratory, diabetes, gastrointestinal, and women's health. 15 state-of-the-art manufacturing facilities support sustainable operations, with 6 research centers and a dedicated workforce of over 26,000 professionals. Lupin continues to expand the healthcare ecosystem through diagnostics, digital health, patient-support programs, and disease management initiatives. Sustainability continues to be a core pillar of the company's business strategy. To learn more, visit or follow us on LinkedIn About YUVEZZI™ YUVEZZI™ (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% is a once-daily, dual-agent eye drop approved by the U.S. Food & Drug Administration (FDA) for the treatment of presbyopia, a condition characterized by the gradual loss of near vision acuity that typically begins around age 45. YUVEZZI combines two medicines that work together to improve close-up vision. Carbachol helps pupils get smaller (or "constrict"), making it easier to focus up close. Brimonidine helps keep pupils from getting too large (or "dilating"). For more information about YUVEZZI and full Prescribing Information, please visit . Eye care professionals can visit for additional resources. YUVEZZI™ Important Safety Information Do not use YUVEZZI if you are allergic to any of its ingredients or if you currently have inflammation of the iris (iritis). Before taking YUVEZZI, tell your doctor if you have depression, low blood pressure, or circulation problems. YUVEZZI may cause temporary blurry, dim, or dark vision. If you experience this, avoid driving, using machinery, and participating in hazardous activities. Use caution when night driving and in other activities in low light. Call your doctor right away if you suddenly have flashes of light, floaters, or vision loss. Do not let the tip of the vial touch your eye, eyelid, or any other surface. The most common side effects of YUVEZZI are headache, impaired vision, and temporary eye pain and/or eye irritation upon use. These are not all of the possible side effects of YUVEZZI. Most side effects were generally mild, didn't last long, and went away on their own. About Tenpoint Therapeutics Tenpoint Therapeutics Ltd. is a commercial-stage ophthalmic pharmaceutical company focused on the commercialization of YUVEZZI™ (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%, the first and only dual-agent eye drop for the treatment of presbyopia, a condition that affects nearly 128 million people in the U.S. and approximately 2 billion people globally.  By understanding real-world needs and partnering with eye care professionals, Tenpoint is working to bring innovation to the aging eye. To learn more, visit Follow us 21% more press release views with Request a Demo

License out/inDrug ApprovalAcquisition

15 Jul 2026

·www.biospace.com

Tenpoint Therapeutics Announces United Kingdom YUVEZZI™ Submission of Marketing Authorization Application to the Medicines and Healthcare Products Regulatory Agency (MHRA) for the Treatment of Blurry Close-Up Vision (Presbyopia) in Adults

YUVEZZI received approval from the U.S. Food and Drug Administration (FDA) in January 2026 as the first and only dual-agent (combination) eye drop approved for the treatment of presbyopia in adults The United Kingdom YUVEZZI submission is an important milestone for Tenpoint Therapeutics’ continued global expansion strategy LONDON & WARREN, N.J.--(BUSINESS WIRE)-- Tenpoint Therapeutics, Ltd. , a global commercial ophthalmic pharmaceutical company focused on developing groundbreaking treatments to improve vision in the aging eye, today announced the submission of a Marketing Authorization Application (MAA) to the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) for the review and approval of YUVEZZI ™ (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% – a once-daily, dual-agent (combination) eye drop – for the treatment of presbyopia in adults. The MAA was submitted via the MHRA’s International Recognition Procedure (IRP), which is a streamlined regulatory pathway, and will consider the U.S. Food and Drug Administration (FDA) approval as part of the Procedure. “Submitting to the MHRA is a meaningful step in our commitment to bringing YUVEZZI to patients beyond the U.S. Blurry close-up vision is among the most prevalent age-related conditions in the UK, affecting a significant proportion of adults over the age of 45, yet currently there are no prescription eye drops approved to help people with their presbyopia,” said Henric Bjarke, Chief Executive Officer of Tenpoint Therapeutics. “If approved, YUVEZZI could help to build a new category of treatment and offer patients in the UK an alternative option for managing the everyday frustrations associated with blurry close-up vision.” Tenpoint Therapeutics is also executing on its plans to submit regulatory applications for YUVEZZI in key regions around the world. Presbyopia is the gradual loss of close-up vision that typically begins around age 45 and affects approximately 2 billion people globally. 1,2,3 Presbyopia can make simple things harder, like reading, texting, or checking labels at the store. 1 The MAA submission is supported by positive data from two Phase 3, randomized, double-masked, controlled studies, BRIO I and BRIO II. In the studies, YUVEZZI significantly improved near vision with one drop, once a day. 4 Additionally, YUVEZZI achieved miosis from 30 minutes up to 10 hours. 4 YUVEZZI was well-tolerated with no treatment-related serious adverse events observed in the more than 72,000 dosing days monitored in BRIO II. 4 About YUVEZZI ™ YUVEZZI ™ (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% is a once-daily, dual-agent eye drop approved by the U.S. Food & Drug Administration (FDA) for the treatment of presbyopia, a condition characterized by the gradual loss of close-up vision that typically begins around age 45. 3,4 YUVEZZI combines two medicines that work together to improve close-up vision. Carbachol helps pupils get smaller (or “constrict”), making it easier to focus up close. Brimonidine helps keep pupils from getting too large (or “dilating”). For more information about YUVEZZI and full Prescribing Information, please visit . Eye care professionals can visit for additional resources. YUVEZZI ™ Important Safety Information Do not use YUVEZZI if you are allergic to any of its ingredients or if you currently have inflammation of the iris (iritis). Before taking YUVEZZI, tell your doctor if you have depression, low blood pressure, or circulation problems. YUVEZZI may cause temporary blurry, dim, or dark vision. If you experience this, avoid driving, using machinery, and participating in hazardous activities. Use caution when night driving and in other activities in low light. Call your doctor right away if you suddenly have flashes of light, floaters, or vision loss. Do not let the tip of the vial touch your eye, eyelid, or any other surface. The most common side effects of YUVEZZI are headache, impaired vision, and temporary eye pain and/or eye irritation upon use. These are not all of the possible side effects of YUVEZZI. Most side effects were generally mild, didn’t last long, and went away on their own. About Tenpoint Therapeutics Tenpoint Therapeutics, Ltd. is a global commercial ophthalmic pharmaceutical company focused on the commercialization of YUVEZZI TM (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%, the first and only dual-agent eye drop for the treatment of presbyopia, a condition that affects nearly 128 million people in the U.S. and approximately 2 billion people globally. 1,3 By understanding real-world needs and partnering with eye care professionals, Tenpoint is working to bring innovation to the aging eye. This press release is intended for US audiences only To learn more, visit tenpointtherapeutics.com and connect on LinkedIn . ____________________ 1 American Optometric Association Health Policy Institute. New Approaches to Presbyopia. 2023. Accessed November 5, 2025. Available at . 2 National Eye Institute. Presbyopia. National Eye Institute. December 4, 2024. conditions-and-diseases/presbyopia . Accessed January 7, 2026. 3 Fricke TR, Tahhan N, Resnikoff S, et al. Global Prevalence of presbyopia and vision impairment from uncorrected presbyopia: systematic review, meta-analysis and modelling. Ophthalmology. 2018;125(10):1492–9. 4 YUVEZZI US Prescribing Information. Visus Therapeutics, Inc.; 2026. Contacts Media: Brandi Robinson media@tenpointtx.com Eye Care Trade Media Michele Gray michele@mgraycommunications.com Investors: Ami Bavishi or Nick Colangelo Gilmartin Group LLC tenpoint@gilmartinir.com

Clinical ResultPhase 3Drug Approval

13 Jul 2026

·www.biospace.com

Tenpoint Therapeutics Announces United Kingdom Submission of Marketing Authorization Application to the Medicines and Healthcare Products Regulatory Agency (MHRA) for the Treatment of Blurry Close-Up Vision (Presbyopia) in Adults

The product, branded YUVEZZI™, received approval from the U.S. Food and Drug Administration (FDA) in January 2026 as the first and only dual-agent (combination) eye drop approved for the treatment of presbyopia in adults The United Kingdom submission is an important milestone for Tenpoint Therapeutics’ continued global expansion strategy LONDON & WARREN, N.J.--(BUSINESS WIRE)-- Tenpoint Therapeutics, Ltd. , a global commercial ophthalmic pharmaceutical company focused on developing groundbreaking treatments to improve vision in the aging eye, today announced the submission of a Marketing Authorization Application (MAA) to the United Kingdom’s MHRA for the review and approval of YUVEZZI ™ (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% – a once-daily, dual-agent (combination) eye drop – that has been developed for the treatment of presbyopia in adults. The MAA was submitted via the MHRA’s International Recognition Procedure, which is a streamlined regulatory pathway, and will consider the U.S. FDA approval as part of the Procedure. Tenpoint Therapeutics is also executing on its plans to submit regulatory applications for the product in key regions around the world. Presbyopia is the gradual loss of close-up vision that typically begins around age 45 and affects approximately 2 billion people globally. 1,2,3 Presbyopia can make simple things harder, like reading, texting, or checking labels at the store. 1 The MAA submission is supported by positive data from two Phase 3, randomized, double-masked, controlled studies, BRIO I and BRIO II. In the studies, the product significantly improved near vision with one drop, once a day. 4,5 Additionally, the product achieved miosis from 30 minutes up to 10 hours. 4 The product was well-tolerated with no treatment-related serious adverse events observed through up to 12 months and >72,000 dosing days. 4,5 About The Product YUVEZZI ™ (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% is a once-daily, dual-agent eye drop approved by the U.S. FDA for the treatment of presbyopia, a condition characterized by the gradual loss of close-up vision that typically begins around age 45. 3,4,5 For more information about the FDA’s approval of YUVEZZI, including its full Prescribing Information, please visit . About Tenpoint Therapeutics Tenpoint Therapeutics, Ltd. is a global commercial ophthalmic pharmaceutical company focused on the commercialization of a product (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%, as a dual-agent eye drop for the treatment of presbyopia, a condition that affects nearly 128 million people in the U.S., up to 30 million in the UK, and approximately 2 billion people globally. 1,3,6 By understanding real-world needs and partnering with eye care professionals, Tenpoint is working to bring innovation to the aging eye. To learn more, visit tenpointtherapeutics.com and connect on LinkedIn . ____________________ 1 American Optometric Association Health Policy Institute. New Approaches to Presbyopia. 2023. Accessed November 5, 2025. Available at . 2 National Eye Institute. Presbyopia. National Eye Institute. December 4, 2024. . Accessed January 7, 2026. 3 Fricke TR, Tahhan N, Resnikoff S, et al. Global Prevalence of presbyopia and vision impairment from uncorrected presbyopia: systematic review, meta-analysis and modelling. Ophthalmology. 2018;125(10):1492–9. 4 Visus Therapeutics, Inc. Data on file. VT-002 Clinical Study Report. 2023. 5 Visus Therapeutics, Inc. Data on file. VT-003 Clinical Study Report. 2025. 6 Association of British Dispensing Opticians. Modern Management of Presbyopia. Part 3: Surgical Methods. Published September 2022. Accessed July 8, 2026. Available at: . Contacts Media: Brandi Robinson media@tenpointtx.com Eye Care Trade Media Michele Gray michele@mgraycommunications.com Investors: Ami Bavishi or Nick Colangelo Gilmartin Group LLC tenpoint@gilmartinir.com

Clinical ResultPhase 3Drug Approval

100 Deals associated with Brimonidine Tartrate

External Link

KEGG	Wiki	ATC	Drug Bank
D02076	Brimonidine Tartrate	S01EA05 D11AX21	DB00484

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Eye Redness	United States	Bausch & Lomb, Inc.	22 Dec 2017
Rosacea	United States	Galderma Laboratories LP	23 Aug 2013
Glaucoma	Japan	Senju Pharmaceutical Co., Ltd.	18 Jan 2012
Ocular Hypotension	United States	AbbVie, Inc.	19 Aug 2005
Glaucoma, Open-Angle	United States	Allergan, Inc.	06 Sep 1996
Ocular Hypertension	United States	Allergan, Inc.	06 Sep 1996

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Seasonal allergic conjunctivitis	Phase 3	United States	Bausch & Lomb, Inc.	18 Nov 2022
Conjunctivitis, Allergic	Phase 3	United States	Bausch & Lomb, Inc.	12 Oct 2022
Capillary Malformations, Congenital, 1	Phase 3	Canada	-	01 Jun 2016
Erythema	Phase 3	United States	Actavis, Inc.	01 Jul 2014
Hyperemia	Phase 3	United States	Bausch & Lomb, Inc.	07 Nov 2013
Hand-Foot Syndrome	Phase 2	France	Tarian Pharma	01 Mar 2026
Peripheral Nervous System Diseases	Phase 2	France	Tarian Pharma	01 Sep 2025
Exanthema	Phase 2	France	Tarian Pharma	20 Jan 2025
Folliculitis	Phase 2	France	Tarian Pharma	20 Jan 2025
Retinal Detachment	Phase 2	United States	Allergan UC	01 Nov 2009

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03193333 (Pubmed \| Clin Ophthalmol)	Phase 3	Glaucoma	43	Timolol, Dorzolamide, and Brimonidine Preservative-Free Fixed Combination	dznscjmadz(jlgplzkhkz) = myonrqbjtl suhcbadutt (ocmpmuumiz ) View more	Positive	01 Feb 2026
				Timolol, Dorzolamide, and Brimonidine with Preservatives Fixed Combination	dznscjmadz(jlgplzkhkz) = jydrtukpvj suhcbadutt (ocmpmuumiz ) View more
BusinessWire Manual	Phase 3	Eye Redness	380	LUMIFY Preservative Free	kgcmeqryke(knkprelbwx) = The study met its primary objective, confirming that LUMIFY Preservative Free is statistically non-inferior to LUMIFY in reducing ocular redness in adults. jdzslymfiw (tmfzghtdid ) Met View more	Non-inferior	29 Jul 2025
				LUMIFY
NCT05591755 (CTgov)	Phase 3	Seasonal allergic conjunctivitis	229	Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution (Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution)	cvhnhtmekp(zlplurflzi) = pfhbyauuoo nsdgvwsdqw (lwqdddadso, 0.6031) View more	-	01 Jul 2025
				Ketotifen fumarate ophthalmic solution 0.035% (Ketotifen Fumarate Ophthalmic Solution 0.035%)	cvhnhtmekp(zlplurflzi) = zdpsmdpbkp nsdgvwsdqw (lwqdddadso, 0.3136) View more
NCT05579730 (CTgov)	Phase 3	Conjunctivitis, Allergic	188	Brimonidine tartrate+ketotifen fumarate (Combination)	iqohbhhnlj(aljxdsdwxc) = iqjmubjgqb qkfxdilhrh (mzabxfwdwi, 0.1464) View more	-	14 Feb 2025
				Ketotifen Fumarate 0.035% (Ketotifen Fumarate)	iqohbhhnlj(aljxdsdwxc) = pxxyqwpgqd qkfxdilhrh (mzabxfwdwi, 0.1487) View more
NCT05360784 (CTgov)	Phase 3	Eye Redness	380	Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation (Brimonidine Tartrate Preservation-free)	fmbwiemgol(pkmzoxqikz) = ikyftpxcxa qeldkjmvka (jcdmwphrfo, 0.039) View more	-	26 Aug 2024
				Lumify® (brimonidine tartrate ophthalmic solution 0.025%) (Lumify®)	fmbwiemgol(pkmzoxqikz) = bfzmeaytry qeldkjmvka (jcdmwphrfo, 0.041) View more
NCT03418727 (CTgov)	Phase 2	Dry Eye Syndromes	84	Corticosteroid+Brimonidine (Brimonidine and Corticosteroid Combination Therapy)	owqypbgadj(tzdeetkunb) = lzjynzohvp mehtahxfig (qyicrwlbfp, vskkbuolbl - abtzjtasgw) View more	-	06 Jul 2022
				Brimonidine (Brimonidine Monotherapy)	owqypbgadj(tzdeetkunb) = cwediidtdt mehtahxfig (qyicrwlbfp, muijyhwegu - znydwgpcwe) View more
NCT03785340 (CTgov)	Phase 3	Dry Eye Syndromes	252	Brimonidine Tartrate	czajisvuei(pnoafmcdqd) = edbkarvikf aedlytiust (fyyyvfgadc, 13.6) View more	-	06 Jun 2022
NCT03760185 (CTgov)	Phase 2	Intraoperative floppy iris syndrome (IFIS)	13	Brimonidine Tartrate (Brimonidine Tartrate 0.2%)	ebcbjuxksi(mhmobwkncy) = rurxxpxneu ytydjzigkr (afjpzytgaw, 2.57) View more	-	20 Apr 2022
				Brimonidine Tartrate (Control - Untreated)	ebcbjuxksi(mhmobwkncy) = gjkxhtlbkq ytydjzigkr (afjpzytgaw, 1.20) View more
NCT03450629 (CTgov)	Phase 3	Glaucoma, Open-Angle	682	Brimonidine Tartrate Ophthalmic Suspension (PDP-716)	ihosxfpzyp(biocybsbwv) = alyuwseeoj xievjzbqjn (fuccpruciz, 3.746) View more	-	15 Feb 2022
				Brimonidine Tartrate Ophthalmic Solution (Brimonidine Tartrate Ophthalmic Solution)	ihosxfpzyp(biocybsbwv) = rwngwoklbs xievjzbqjn (fuccpruciz, 3.724) View more
NCT03782701 (CTgov)	Phase 4	Blepharoptosis	43	Brimonidine tartrate ophthalmic solution 0.025% (Lumify Eye Drop)	ehfbmsudgm(iolutkojkw) = mygjngbede iiftpawzkr (iavbalphxp, 1.71) View more	-	14 Jun 2021
				Sterile balanced saline solution (Saline Solution Eye Drop)	ehfbmsudgm(iolutkojkw) = lesyashael iiftpawzkr (iavbalphxp, 1.62) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis